Blueprint Medicines Statistics
Share Statistics
Blueprint Medicines has 64.58M
shares outstanding. The number of shares has increased by 2.06%
in one year.
| Shares Outstanding | 64.58M |
| Shares Change (YoY) | 2.06% |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,862 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 5.66M, so 8.76% of the outstanding
shares have been sold short.
| Short Interest | 5.66M |
| Short % of Shares Out | 8.76% |
| Short % of Float | 9.86% |
| Short Ratio (days to cover) | 7.26 |
Valuation Ratios
The PE ratio is -81.72 and the forward
PE ratio is 99.44.
Blueprint Medicines's PEG ratio is
0.94.
| PE Ratio | -81.72 |
| Forward PE | 99.44 |
| PS Ratio | 10.77 |
| Forward PS | 4 |
| PB Ratio | 18.36 |
| P/FCF Ratio | -27.8 |
| PEG Ratio | 0.94 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Blueprint Medicines.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.85,
with a Debt / Equity ratio of 1.57.
| Current Ratio | 2.85 |
| Quick Ratio | 2.8 |
| Debt / Equity | 1.57 |
| Debt / EBITDA | 24.39 |
| Debt / FCF | -2.38 |
| Interest Coverage | -3.08 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $746,076.25 |
| Profits Per Employee | $-98,370.97 |
| Employee Count | 682 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.48 |
Taxes
| Income Tax | 1.23M |
| Effective Tax Rate | -1.86% |
Stock Price Statistics
The stock price has increased by -1.31% in the
last 52 weeks. The beta is 0.83, so Blueprint Medicines's
price volatility has been higher than the market average.
| Beta | 0.83 |
| 52-Week Price Change | -1.31% |
| 50-Day Moving Average | 91.27 |
| 200-Day Moving Average | 93.31 |
| Relative Strength Index (RSI) | 60.47 |
| Average Volume (20 Days) | 977,055 |
Income Statement
In the last 12 months, Blueprint Medicines had revenue of 508.82M
and earned -67.09M
in profits. Earnings per share was -1.07.
| Revenue | 508.82M |
| Gross Profit | 488.66M |
| Operating Income | -212.04M |
| Net Income | -67.09M |
| EBITDA | 19.23M |
| EBIT | 2.94M |
| Earnings Per Share (EPS) | -1.07 |
Full Income StatementBalance Sheet
The company has 102.01M in cash and 469.11M in
debt, giving a net cash position of -367.09M.
| Cash & Cash Equivalents | 102.01M |
| Total Debt | 469.11M |
| Net Cash | -367.09M |
| Retained Earnings | -2.41B |
| Total Assets | 1.2B |
| Working Capital | 451.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -192.59M
and capital expenditures -4.63M, giving a free cash flow of -197.22M.
| Operating Cash Flow | -192.59M |
| Capital Expenditures | -4.63M |
| Free Cash Flow | -197.22M |
| FCF Per Share | -3.14 |
Full Cash Flow StatementMargins
Gross margin is 96.04%, with operating and profit margins of -41.67% and -13.19%.
| Gross Margin | 96.04% |
| Operating Margin | -41.67% |
| Pretax Margin | -12.94% |
| Profit Margin | -13.19% |
| EBITDA Margin | 3.78% |
| EBIT Margin | -41.67% |
| FCF Margin | -38.76% |
